Investigators on the CLL Moon Shot team are rendering the chemotherapy approach to CLL obsolete with new targeted therapies and immunotherapy approaches that have fewer and less harsh side effects. They’ve launched a 208-patient clinical trial with ibrutinib, a recently approved drug that produces durable responses with less toxicity, to test it in combination therapy and understand how CLL resists treatment.
About Leukemia (CLL)
A slow killer
CLL develops slowly, creating defective white blood cells that can’t produce antibodies against infection. The average age of patients at diagnosis is 72. As more people age, more will develop CLL.